RNA interference therapeutics in organ transplantation:The dawn of a new era by Bruggenwirth, Isabel M. A. & Martins, Paulo N.
 
 
 University of Groningen
RNA interference therapeutics in organ transplantation
Bruggenwirth, Isabel M. A.; Martins, Paulo N.
Published in:
American Journal of Transplantation
DOI:
10.1111/ajt.15689
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Final author's version (accepted by publisher, after peer review)
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Bruggenwirth, I. M. A., & Martins, P. N. (2019). RNA interference therapeutics in organ transplantation: The
dawn of a new era. American Journal of Transplantation. https://doi.org/10.1111/ajt.15689
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
This article has been accepted for publication and undergone full peer review but has not been through the 
copyediting, typesetting, pagination and proofreading process, which may lead to differences between this 
version and the Version of Record. Please cite this article as doi: 10.1111/AJT.15689
This article is protected by copyright. All rights reserved
MS ISABEL M.A. BRÜGGENWIRTH (Orcid ID : 0000-0002-8557-7081)
Article type      : Minireview
RNA Interference Therapeutics in Organ Transplantation
Isabel M.A. Brüggenwirth, BSc 1 and Paulo N. Martins, MD, PhD2
1. Department of Surgery, Section of Hepato-Pancreato-Biliary Surgery and Liver 
Transplantation, University Medical Center Groningen, Groningen, The Netherlands 
2. Department of Surgery, Division of Organ Transplantation, UMass Memorial Medical 



















DGF, delayed graft function
dsRNA, double-stranded RNA
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HMGB-1, high-mobility group box 1 
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Abstract
RNA interference (RNAi) is a natural process through which double-stranded RNA molecules can 
silence the gene carrying the same code as the particular RNA of interest. In 2006, the discovery 
of RNAi was awarded the Nobel Prize in Medicine and its success has accumulated since. Gene 
silencing through RNAi has been used successfully in a broad range of diseases, and, more 
recently, this technique has gained interest in the field of organ transplantation. Here, genes related 
to ischemia-reperfusion injury (IRI) or graft rejection may be silenced to improve organ quality 
after transplantation. Several strategies have been used to deliver siRNA, and pre-transplant 
machine perfusion presents a unique opportunity to deliver siRNA to the target organ during ex 
situ preservation. In this review, the potential of RNAi in the field of organ transplantation will be 
discussed. A brief overview on the discovery of RNAi, its mechanism and limitations are 
included. In addition, studies using RNAi to target genes related to IRI in liver, kidney, lung, and 
heart transplantation are discussed. 
1. Introduction
Organ transplantation is often the only treatment for end-stage organ failure, such as for 
liver, kidney, lung, and heart. The ongoing discrepancy between transplant candidates and 
available organs has urged transplant centers to use more suboptimal organs, which are known to 
be more vulnerable to ischemia-reperfusion injury (IRI) compared to standard grafts. Mitigation of 
IRI should drive the utilization of suboptimal organs in order to address the shortfall in donor 
grafts. Hence, the evolutionary discovery of RNA interference (RNAi) holds potential to silence 
genes related to IRI and reduce graft injury after transplantation.1 In addition, genes contributing 
to graft rejection may be silenced.
In this review, we will present a brief history of RNAi and describe the mechanisms by 
which gene silencing is induced. We will present an overview of recent literature on RNAi in the 
field of liver, kidney, lung, and heart transplantation, and we will focus on machine perfusion as a 
potential delivery platform for RNAi in organ transplantation. Finally, several limitations 
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In the early 1980s, it was revealed in Escheria coli that small RNA molecules can bind to a 
complementary sequence in messenger RNA (mRNA) and inhibit translation.2 More than a decade 
later, the American scientists Fire and Mello were the first to describe that double-stranded RNA 
(dsRNA) molecules can silence the gene carrying the same code as the particular RNA of interest, 
the mechanism referred to as RNAi.3 Despite the potency of RNAi, the technique could not yet be 
used for any therapeutic purposes in mammalian cells, because of long dsRNA activating a panic 
response in eukaryotic cells.1 This problem was overcome with the discovery of so-called small 
interfering RNA (siRNA). It was demonstrated that after dsRNA enters the cell cytoplasm, an 
enzyme called ‘Dicer’ cleaves the dsRNA into smaller 21-23 base-pairs, called siRNA. Then, 
Argonaute protein in RNA-induced silencing complex (RISC) unwinds the double stranded 
siRNAs. One strand of the siRNA is removed (passenger strand), leaving the remaining strand 
available to bind to mRNA target sequences by Watson-Crick base pairing principle. The target 
mRNA is degraded, or its translation repressed, thereby blocking target gene’s expression (Figure 
1). 
In 2001, Elbashir and colleagues were the first to demonstrate that synthetic siRNA was 
able to induce RNAi in mammalian cells.4 Since, a series of important and wide-ranging diseases 
have been targeted using siRNA-based therapies.5 In 2006, the discovery of RNAi was awarded 
the Nobel Prize in Medicine, which further attracted a lot of research into this field. Another 
milestone was reached in 2018, when the United States Food and Drug Administration approved 
the first RNAi therapeutic treatment for a rare form of amyloidosis.5 At least six other RNAi 
therapeutics are already in phase III clinical trials, of which one targets p53 to reduce the 
incidence of delayed graft function (DGF) after kidney transplantation. Nonetheless, the progress 
of siRNA has been a roller-coaster ride driven not only by science, but also regulatory trends, the 
stock markets, and big pharma businesses (Figure 2).6 
Currently, four types of small RNA are used in clinical trials, including siRNA, 
microRNA, short hairpin RNA (shRNA), and dicer substrate RNA.5  These types differ in their 
biosynthetic pathway, the types of RISC they use, and the duration of silencing.
1.2. Delivery strategies for siRNA
The utility of RNAi therapy relies on effective delivery of the siRNA to the site of protein 
synthesis, and there are a number of factors that limit its therapeutic utility, such as unstable 
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target effects.7 Chemical modification techniques can improve serum stability and increase the in 
vivo half-life and cellular uptake of siRNA. Other efficient ways to deliver siRNA molecules into 
host cells is by using viral vectors (e.g. lentiviral, adenovirus) or non-viral vectors (e.g. cationic 
lipids, polymers, and inorganic nanoparticles).5 Viral vectors tend to have a higher transduction 
efficiency and a higher gene-silencing effect in most target cells compared to non-viral vectors. 
The downsides of viral vectors are however, the low specificity of the virus carrier, possible 
activation of the host cell oncogenes when a viral vector itself is randomly inserted in the host cell 
genome, and high costs. Multi-component non-viral vectors are encumbered by the need for 
intravenous administration, and in the case of lipid nanoparticles, pre-medication with steroids to 
mitigate infusion-related reactions. Also, exosomes are natural bio-carriers that have been 
investigated for the delivery of siRNA. Exosomes are suitable for hosting soluble drugs, have a 
high capacity for overcoming biologic barriers, cause few off-target effects, and have low 
immunogenicity. The therapeutic window of nanocarriers could be increased by targeted delivery, 
which can further reduce off-target effects and increase bioavailability of the therapeutic agent at 
the target site. Targeted delivery is usually achieved by adding a ligand, such as an aptamer or 
peptide, to the naked small RNA or to the nanoparticle. 
In case of organ transplantation in particular, ex situ machine perfusion can be an attractive 
approach for targeted siRNA-delivery to the organ during preservation.8 It prevents filtration by 
other organs, enzymatic degradation of siRNA in the serum, and off-target effects. Also, it is 
clinically more applicable, because RNAi-treatment to individual organs can take place after organ 
procurement, instead of treating the donor systemically. Thereby, ethical issues regarding 
premortem treatment of the controlled donation after circulatory are overcome, and regulatory 
issues in the multi-organ donor can be prevented so that only the target organ is treated by RNAi 
without the need for agreement of other transplant teams. After machine perfusion, the organ is 
flushed to remove the previously circulating machine perfusion solution, thereby also removing 
excess of circulating siRNA to prevent off-target effects in the recipient. 
2. RNA interference and organ transplantation 
In this section we will give an overview of the recent literature on RNAi in the field of 
solid organ transplantation. Figure 3 shows the number of in vivo studies using RNAi in organ 
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2.1. Liver transplantation
Several preclinical studies have been performed using RNAi to silence genes related to 
liver IRI (Table 1). Hence, Zhao et al. targeted high-mobility group box 1 (HMGB-1), an early 
mediator of post-reperfusion injury and inflammation, in a mice model.9 The authors demonstrate 
improved liver function after reperfusion in the RNAi-treated group. Another study assessed the 
effects of siRNA targeting RelB, critical to both the regulation of apoptosis and increased 
expression of proinflammatory cytokines.10 Systemic injection of RelB siRNA 24 hours before 
liver ischemia effectively reduced the level of RelB, and protected livers against IRI with reduced 
oxidative stress and a lower inflammatory response. Contreras and colleagues evaluated silencing 
of proapoptotic caspases 3 and 8 in a murine model of liver IRI.11 The siRNA-treated mice 
showed a remarkable survival benefit with 30% of animals given caspase-8 siRNA and 50% of 
animals given caspase-3 siRNA surviving more than 30 days, whereas all of the control mice died 
within 5 days after the ischemic event. 
Compared to siRNA, shRNA has also been used to target genes related to liver IRI. For 
example, silencing of NACHT domain, leucine-rich repeat domain, and pyrin domain-containing 
protein-3 (NALP3) was achieved in murine livers using shRNA against NALP3.12 During IRI, 
NALP3 is pivotal in releasing inflammatory cytokines. Consequently, shRNA-treatment decreased 
release of cytokines, serum alanine aminotransferase levels (ALT), and inflammatory cell 
infiltration. Similarly, Hernandez-Alejandro et al. injected mice with tumor necrosis factor alpha 
(TNF) shRNA 2 days prior to hepatic ischemia.13 TNF expression was significantly suppressed, 
and 6 hours after reperfusion, shRNA-treated mice showed lower peak ALT and improved liver 
histology compared to controls. Schneider and colleagues reduced expression of profyl 
hydroxylase domain enzyme 1 (PHD1) to protect hepatocytes against hypoxic damage and 
mitigate IRI.14 Short hairpin RNA against PHD1 was administered intravenously with a viral 
vector in mice 5 days prior to ischemia. Serum ALT levels were reduced in shRNA-treated mice, 
and silencing of PHD1 attenuated hepatocyte death induced by IRI. While most small animal 
studies used hydrodynamic injection of siRNA, this approach is not practical for clinical use. High 
dosage can result in more off-target effects and large amounts of siRNA are costly. As such, lipid 
nanoparticles have attracted much interest given its high hepatic retention after intravenous 
administration.15 In addition, Jiang et al. were the first to report on liver-specific liposome-based 
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with galactose, which binds to the asialoglycoprotein receptor that is expressed on the surface of 
hepatocytes. 
Recently, research from our group reported for the first time the use of siRNA during liver 
machine perfusion.17 It was demonstrated that Fas siRNA directly added to the perfusion solution 
can be successfully delivered to rat liver grafts during both hypothermic and normothermic 
machine perfusion. Successful transfection into hepatocytes was achieved by coating siRNA with 
lipid nanoparticles (LNPs). Future studies using transplantation models should further investigate 
the effects of siRNA therapy during machine perfusion.
2.2. Kidney transplantation
The kidney could be an excellent target for RNAi therapy due to its unique characteristics 
of the urological system, which can lead to rapid uptake of siRNA. Various preclinical studies in 
kidney have been performed (Table 2) and, recently, a phase III multi-center trial to evaluate the 
inhibition of DGF by p53 siRNA in kidney transplant patients has been initiated by Quark 
Pharmaceuticals (www.clinicaltrials.gov).
Yang and colleagues have performed several studies aimed at silencing caspase 3, a key 
player in kidney IRI.18–20 First, they showed renoprotection of naked caspase 3 siRNA in a porcine 
ex situ isolated reperfusion model.20 Caspase 3 siRNA was infused into the renal artery before 
static cold storage (SCS) and added to autologous blood during 3-hour reperfusion. In the siRNA-
treated group, apoptosis was significantly decreased, renal oxygenation was improved, and these 
kidneys showed a more favorable blood pH. In a follow-up study, using a porcine auto-
transplantation model, they found that levels of caspase 3 were only downregulated during cold 
storage, but no longer after kidney transplantation.18 The authors suggest poor stability of naked 
siRNA and/or systemic complementary effects overcoming the local effect. Concordantly, they 
performed a study using chemically modified naked caspase 3 siRNA in a porcine auto-
transplantation model.19 Caspase 3 siRNA was infused into the renal artery before SCS and 
administered intravenously to the recipient pig. As a result, caspase 3 was downregulated after 
SCS preservation and after transplantation, with improved renal function compared to controls. 
Kidney IRI has also been associated with activation of the complement system. In a mice 
model, silencing of complement factor C5a was achieved by administering C5a siRNA two days 
before induction of renal ischemia.21 Treatment with siRNA preserved renal function from IRI, as 
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decreased complement-mediated IRI effects and a survival benefit after silencing complement 3 in 
mice.22 The same group also used a combination of siRNAs targeting complement 3 and caspase 
3, highlighting the potential of targeting multiple genes.23 As such, Zhang et al. show a survival 
benefit after targeting both caspase 3 and caspase 8 in a mice clamping model.24 
On another note, there is growing evidence that T cells participate in kidney IRI in an 
antigen-dependent manner. CD40 is a co-stimulatory molecule which participates in T-cell 
proliferation and other effector functions. Consequently, blockade of CD40 with siRNA improved 
renal inflammatory status in a rodent transplantation model.25 
RelB and inhibitory kB kinase, both components of the NF-kB family, have also 
effectively been silenced in kidney models.26,27 Survival experiments after RelB-siRNA show a 
huge advantage in 8-day survival rates: 80% in siRNA-treated mice compared to 10% of control 
mice. 
Zheng et al. were the first to demonstrate gene silencing in a mice kidney transplantation 
model after kidney machine perfusion with a siRNA cocktail.28 Treatment with siRNA targeting 
complement 3, RelB, and Fas decreased IRI, and improved kidney function and graft survival after 
transplantation. When cold ischemia time was prolonged, the siRNA-treated donor kidneys had 
much lower blood urea nitrogen and serum creatinine compared to controls, indicating that the 
siRNA cocktail attenuated renal dysfunction induced by prolonged cold ischemia time. 
2.3. Lung transplantation
To achieve pulmonary delivery of siRNA, the most non-invasive way is through 
inhalation. Intratracheal administration and intranasal delivery are commonly used in animal 
experiments (Table 3), but the clinical application of these routes is limited. Intratracheal 
administration uses an invasive setup and uncomfortable technique, whereas intranasal 
administration is disadvantageous in humans because our nasal cavity filters out the majority of 
particles. Therefore, pulmonary RNAi delivery systems should consider careful control of particle 
or droplet size to bypass the lungs natural defense mechanisms. 
The Fas cascade is one of the most powerful pathways initiating apoptosis and 
inflammation in lung IRI. Del Sorbo et al. administered siRNA targeting Fas intratracheally in 
mice 2 days before inducing ischemia.29 After reperfusion, silencing of Fas was found to decrease 
edema formation, improve lung compliance, and reduced cell apoptosis. Caspases also play a 
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after administering shRNA in a rat model of lung IRI.30 Animals treated with shRNA showed 
increased partial pressures of oxygen, and decreased partial pressures of carbon dioxide. In a rat 
autotransplantation model, Chi and colleagues used RNAi to target myeloid differentiation 
protein-2 (MD-2), which plays a key regulatory role in TLR activation and the inflammatory 
response during lung IRI.31 Downregulation of MD-2 reduced water content of the lungs, and 
increased partial oxygen pressures with less acute lung injury after transplantation. Lv et al. used a 
model of rat lung transplantation to show successful silencing of p38 mitogen-activated protein 
kinase, which is a crucial signaling enzyme involved in inflammation and apoptosis.32 Rats were 
administered p38a shRNA 2 days before ischemia, and treated animals showed a significant 
reduction in lung expression of p38a with reduced apoptosis and improved lung function. 
Recently, the group from Hannover performed the first study using normothermic ex vivo lung 
perfusion (EVLP) to achieve so-called ‘immunological invisibility’ of the donor organ.33 Silencing 
major histocompatibility complex (MHC) expression in lungs could lead to reduced graft 
rejection, thereby also reducing the hindersome side effects of lifelong immunosuppression. The 
study from Figueiredo et al. used delivery by lentiviral vectors with shRNA against swine 
leukocyte antigen during 2 hours EVLP. Their results demonstrated the feasibility of genetically 
engineering all lung regions. Moreover, perfusion with lentiviral vectors did not induce additional 
tissue injury, therefore not compromising the beneficial effect of EVLP. 
2.4. Heart transplantation
Multiple studies have targeted genes related to ischemic injury after myocardial infarction, but 
only few reports focus on IRI in heart transplantation in particular (Table 4). The unique structure 
of the cardiac muscle having a compact extracellular matrix filled with negatively charged 
molecules disrupts small RNA delivery using conventional carriers. Therefore, successful cardiac 
applications of RNAi must be preceded by the development of optimally designed delivery 
systems. A commonly used delivery method is by using facial amphipathic bile acids (deoxycholic 
acid) conjugated with a polymer.34 Immune tolerance leading to permanent acceptance of heart 
transplants without immune rejection is a lofty goal for cardiac transplantation. To decrease graft 
rejection after transplantation, studies have targeted different TLRs and T-cell pathways using 
RNAi. In a mice model of heart transplantation, shRNA was used to block the co-stimulatory 
pathway B7/CD28/CTLA-4 through gene modification of dendritic cells (DCs).35 Rats were 
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Gene manipulation in DCs can decrease its allostimulatory capacity, which makes these cells more 
‘tolerogenic’. Besides, DCs express high levels of MHC molecules and costimulatory molecules 
CD40 and CD80, necessary for T cell proliferation, differentiation, and survival. Activation of T 
cells without co-stimulation may lead the development of immune tolerance. A study investigated 
silencing of both CD40 and CD80 by administering siRNA to the recipient 3 days prior to heart 
transplantation and up to 3 weeks after transplantation of a fully MHC-mismatched heart.36 RNAi 
treatment significantly improved graft survival and 67% of recipients achieved tolerance to the 
transplanted heart. Zhang and colleagues blocked TLR-signaling by RNAi therapy against adaptor 
molecules myeloid differentiation primary response 88 (MyD88) and TIR-domain-containing 
adapter-inducing interferon- (TRIF).37 Recipient mice were treated with MyD88 and TRIF 
siRNA vectors before and after transplantation of a fully MHC-mismatched heart. While untreated 
grafts only survived 5–8 days, siRNA treatment significantly prolonged graft survival with a 
median of 37 days. Several years later, Wang et al. also used RNAi to silence MyD88 and TIRF in 
a mice heart transplantation model.38 In addition, they targeted mammalian target of rapamycin 
(mTOR), a critical signaling kinase. Graft survival was significantly extended compared to 
controls, and immune rejection was prevented through silencing of TRL and mTOR pathways. 
Instead of treating the recipient, Zheng et al. preserved mice heart grafts in cold University of 
Wisconsin solution containing TNF, complement 3, and Fas siRNAs.39 Preservation in the 
siRNA-containing solution knocked down gene expression after transplantation. Moreover, treated 
heart grafts retained strong beating for more than 100 days, whereas all control grafts lost function 
within 8 days. 
Recently, Wei et al., for the first time, used 3-hour hypothermic machine perfusion of mini 
pig donor hearts with a solution containing siRNAs targeting complement 3, caspase 8, caspase 3, 
and NF-kB-p65 genes.40 Both ex situ reperfusion and orthotopic transplantation models showed 
beneficial effects after siRNA perfusion. RNAi therapy reduced cardiac IRI and improved graft 
function after transplantation. 
3. Limitations of RNA interference therapeutics 
Despite very promising therapeutic outcomes, widespread clinical applicability of RNAi is 
hindered by several limitations.41 Stable delivery of small RNAs to the target cells/organ may be 
limited by filtering by the lungs, liver, or kidneys. Moreover, extracellular unstable small RNAs 
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life. Small interfering RNA also has poor cellular uptake because of their high molecular weight 
and negative charge, so that they are not easily able to cross cell membranes via passive diffusion. 
Some RNAi-delivery strategies take advantage of endocytosis, but degradation or entrapment 
inside the endosome should be taken into consideration. Once in the cell cytoplasm, small RNAs 
remain vulnerable to degradation by intracellular RNAses and need to be recognized by and 
incorporated into RISC. It should also be noted that several ways of delivery that have been used 
in animal models (e.g. intratracheal delivery or intramyocardial injection) may not be applicable 
for clinical use.
Besides delivery challenges, RNAi might cause problems by silencing of non-targeted 
genes.42 Off-target silencing is undesirable as it can lead to dangerous mutations of gene 
expression and unexpected cell transformation. Some small RNAs and miRNAs share their 
mechanisms of action. For example, long-term overexpression of shRNA may affect endogenous 
miRNAs, impeding their regulatory functions and inducing toxicity. This was supported by the 
observation that miRNAs in hepatocytes were downregulated after transfection with high levels of 
shRNA, leading to morbidity in mice.43 However, the risk of oversaturating small RNA pathways 
can be minimized by optimizing dosage and sequence. Hence, monitoring and controlling 
intracellular siRNA levels is imperative for stable gene silencing, while mitigating adverse effects. 
Though generally well-tolerated, small RNAs can activate the host immune response in a 
dose-dependent manner. Activation of the immune system might originate from the delivery 
vehicle (e.g. viral vectors) or from the process of RNAi itself. Studies have shown that siRNAs 
may trigger immune activation through interferon responses and TLR pathways.44,45 
4. Conclusions
Since the discovery of RNAi, studies using this technique have rapidly accumulated in all 
fields of medicine. More recently, attention is given to RNAi as a technique to target genes related 
to IRI or graft rejection after organ transplantation and improve outcomes. It is exciting that first 
attempts have been made to translate RNAi therapy to the clinic, such as to decrease the incidence 
of DGF after kidney transplantation by silencing the p53 gene. However, a number of factors 
stand in the way of widespread therapeutic potential, such as stable delivery to the target 
cells/organ, immune responses, and undesired off-target effects. Hence, ex situ machine perfusion 
can offer a unique opportunity to deliver siRNA to the target organ with multiple benefits, such as 
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results are promising, studies using RNAi during machine perfusion preservation are still very 
limited, and there are yet many uncertainties, such as optimal small RNA dosage, perfusion 
temperature, or perfusion duration. Ex situ organ machine perfusion is currently performed in 
kidney, lung, liver and heart transplantation and should be considered a realistic option for RNAi 
treatment since the benefits may be multiform. RNAi as a therapeutic agent is still in its infancy, 
but will definitely have an impactful effect in the field of organ transplantation in the near future. 
Disclosure
The authors of this manuscript have no conflicts of interest to disclose as described by the 
American Journal of Transplantation. 
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Figure legends 
Figure 8.1. Schematic illustration of RNAi mechanism. Double stranded RNA (dsRNA) 
molecule binds to a Dicer protein, which cleaves it into small interfering RNA (siRNA). These 
siRNAs bind to an Argonaute protein, which is part of the RNA-induced silencing complex 
(RISC). The RISC separates the siRNAs in two strands: the passenger strand (blue) is degraded, 
while the guide strand (orange) serves as a search probe, which links RISC to complementary 
RNA targets. After this recognition target’s expression can be regulated through several different 
mechanisms. 
Figure 8.2. Major events on the histology of RNAi and the effect on market size, optimism, 
and visibility. Figure adapted from Khvorova et al. [6].
Figure 8.3. Major events in the history of RNAi.  Events since the first description of RNAi in 
1998 and the number of publications of in vivo studies RNAi in liver, kidney, lung, and heart 
transplantation.
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Table 1. In vivo studies on RNA interference in liver transplantation  
 
Model Administration Target Type Delivery method Dose Main outcome in treated groups 
compared to controls 
Mice segmental 
hepatic IRI [9] 
Intravenous injection 48 h before 
ischemia 
HMGB-1 siRNA PEI vector 50 g pathological damage, expression of 
proinflammatory receptors 
Mice segmental 
hepatic IRI [10] 
Intravenous injection 24 h before 
ischemia 
RelB miRNA Expression vector 50 g AST, MDA, MPO serum levels 
Mice segmental 
hepatic IRI [11] 




siRNA Lipiodol 0.5 nmol >30 days survival: 30% in caspase-8 
treated, and 50% in caspase-3 treated. 0% 
survival on postop day 5 in controls. 
Mice segmental 
hepatic IRI [12] 
Intravenous injection 48 h before 
ischemia 
NALP3 shRNA Expression vector 100 g AST, proinflammatory cytokines,  
inflammatory cell infiltration 
Mice segmental 
hepatic IRI [13] 
Intravenous injection 48 h before 
ischemia 
TNF shRNA Expression vector 50 g AST/ALT, improved histology, MDA 
Mice segmental 
hepatic IRI [14] 
Intravenous injection before 
ischemia 
PHD1 shRNA Adenoviral vector  ALT, oxidative stress, improved 
histology 
Mice segmental 
hepatic IRI [16] 
Intravenous injection 6 h before 
ischemia 
TLR4 siRNA Galactose-conjugated 
liposome nanoparticles 
50 g ALT/AST, improved histology, MPO, 
MDA, ROS, inflammatory cytokines 
Rat liver machine 
perfusion [17] 
Hypothermic and normothermic 
machine perfusion 




Portal vein injection 72 h before 
ischemia 
LXR  Lentiviral vector  fatty acid accumulation, improved 
survival  
Rat segmental hepatic 
IRI [2*] 
Intravenous injection 1 h before 
ischemia 
HSP72 siRNA Ultrasound microbubble 
contrast agent 
20 l ALT, TNF. Ultrasound radiation 
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bubble only.  
Rat liver 
transplantation [3*] 
4-minute portal vein perfusion IRAK-4 shRNA Expression vector  Improved liver function and less histologic 
liver injury  
 
ALT = alanine aminotransferase; AST = aspartate aminotransferase; HMGB-1 = high-mobility group box 1; HSP72 = heat shock protein 72; 
IRAK-4 = interleukin-1 receptor-associated kinase-4; IRI = ischemia-reperfusion injury; LXR = liver X receptor alpha; MDA = 
malondialdehyde; MPO = myeloperoxidase; NALP3 = NACHT domain, leucine-rich repeat domain, and pyrin domain-containing protein-3; PEI 
= polyethyleneimine; PHD1 = profyl hydroxylase domain enzyme 1; ROS = reactive oxygen species; siRNA = small interfering RNA; shRNA = 
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Table 2. In vivo studies on RNA interference in kidney transplantation 
 




Infusion with UW into the renal 
artery during 24-hour SCS  
Caspase 3 siRNA Chemically modified 
(locked nucleic acid) 




Infusion with UW into the renal 
artery during 24-hour SCS + 
intravenous injection in the 
recipient before transplantation 
Caspase 3 siRNA Chemically modified 
(locked nucleic acid)  
0.3 mg Caspase-3 knockdown after SCS and Tx. 
apoptosis, inflammation, improved renal 
function 
Pig renal clamping and 
ex vivo reperfusion [20] 
Infusion with UW into the renal 
artery during 24-hour SCS. 
Infusion into autologous blood.  
Caspase 3 siRNA Chemically modified 
(locked nucleic acid)  
3 g/ml, 0.15 
g/ml 
apoptosis, inflammation, doubled in 
oxygen consumption, neutralized perfusate 
pH, renal blood flow 
Mice renal clamping 
[21] 
Intravenous injection 48 h before 
ischemia 
C5a siRNA Expression vector 50 g BUN, serum creatinine, proinflammatory 
cytokines, neutrophil influx, cell necrosis 
Mice renal clamping 
[22] 
Intravenous injection 48 h before 
ischemia 
C3 shRNA Expression vector 50 g complement-mediated IRI, improved renal 
function, mortality 
Mice renal clamping 
[23] 




siRNA Expression vector 50 g BUN, creatinine, mortality. Reduction in 
histopathological injury.  
Mice renal clamping 
[24] 
Intravenous injection 48 h before 
ischemia 
Caspase 3 
and 8  
siRNA Expression vector 50 g Significant survival benefit  
Rat kidney 
transplantation [25] 
Intravenous injection 1 h before 
nephrectomy in the donor and 
before reperfusion in the recipient 
CD40 siRNA Chemically stabilized 
(backbone 
modification) 
15–500g Improved renal inflammatory status, TNF. 
Renoprotection after transplantation  
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ischemia damage scores 
Mice renal clamping 
[27] 
Intravenous injection 48 h before 
ischemia 
RelB siRNA Expression vector 50 g 90% of control mice died from lethal IRI, 
80% treated mice survived up to day 8 
Mice kidney 
transplantation [28] 




siRNA Naked 100 g Controls died around day 40, compared to 
treated animals who survived >80 days 
Rat kidney 
transplantation [*4] 
In situ perfusion with UW solution SHARP-2 shRNA Lentiviral construct  Prolonged survival by 4–5 days 
Mice renal clamping 
[*5] 
Transarterial injection after IRI p53 shRNA Expression vector, 
polymer 
0.33 g / 3.3 
g 
apoptosis, creatinine, improved histology 
Rat renal clamping [*6] Intravenous injection between 16 h 
before – 8 h after ischemia 
p53 siRNA Lipid nanoparticle 12 mg/kg Rapid delivery of siRNA to proximal tubule 
cells, apoptosis, improved histology  
Mice renal clamping 
[*7] 




shRNA Expression vector 150 g BUN, creatinine, renal tubular injury 
Mice renal clamping 
[*8] 
Intravenous injection 48 h before 
ischemia 
TNF siRNA Expression vector  50 g 90% of control mice died from lethal IRI, 
50% treated mice survived up to day 8 
 
BUN = blood urea nitrogen; C3 = complement 3; C5 = complement 5; SCS = static cold storage; siRNA = small interfering RNA; SHARP-2 = 
split- and hairy-related protein 2; shRNA = short hairpin RNA; TNF = tumor necrosis factor alpha; UW = University of Wisconsin; IKK = 
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Table 3. In vivo studies on RNA interference in lung transplantation  
 
Model Administration Target Type Delivery method Dose Main outcome in treated groups 
compared to controls 
Mice lung ischemia 
and ex situ reperfusion 
[29] 
Intratracheal treatment 48 h 
before ischemia 
Fas siRNA Naked 100 L edema, improved lung compliance, 
apoptosis 
Rat lung clamping 
[30]  
Intratracheal treatment 48 h 
before ischemia 
Caspase 3 shRNA Viral vector 30 g Protection lung function,  paO2,  paCO2 
Mice lung 
transplantation [31] 
Endotracheal treatment 48 h 
before ischemia 
MD-2 siRNA Lipid vector  pathology of acute lung injury, improved 
paO2, proinflammatory cytokines 
Rat lung 
transplantation [32] 
Intratracheal treatment 48 h 
before ischemia 
p38 shRNA Expression vector 2 g pulmonary vein O2 level, wet weight-
to-dry weight ratio, lung injury score, 
proinflammatory cytokines, apoptosis 
Pig machine perfusion 
[33] 
2-hour normothermic EVLP   SLA I and II shRNA Viral vector  Feasibility of genetical engineering of all 
lung regions. Silencing >50%. No effect 
on cell viability of tissue integrity.  
 
MD-2 = myeloid differentiation protein-2; paCO2 = partial carbon dioxide pressure; paO2 = partial oxygen pressure; shRNA = short hairpin 
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Table 4. In vivo studies on RNA interference in heart ischemia and transplantation 
 
Model Administration Target Type Delivery method Dose Main outcome in treated groups 




immediately after ischemia 
B7/CD28 shRNA Expression vector 100 g survival time, organ rejection 
Mice heart 
transplantation [36] 
Intravenous injection 3 days 
before transplantation, and 7, 14, 
21 days after transplantation 
CD40/CD80 shRNA Expression vector 50 g survival  
Mouse heart 
transplantation [37] 
Intravenous injection 3, 7 days 
before transplantation and 7, 14 
days after transplantation 
MyD88, 
TRIF 
siRNA Expression vector  Prolonged graft survival  
Mouse heart 
transplantation [38] 
Intravenous injection 3, 7 days 
before transplantation and 7, 14, 
21 days after transplantation 
MyD88, 
TRIF, mTOR 
siRNA Expression vector 50 g Prolonged graft survival  
Mouse heart 
transplantation [39] 
Preservation in UW solution  TNF, C3, 
Fas 
siRNA Expression vector 2 g Strong heart beats >100 days after 
transplantation in treated animals versus 
loss of graft function <8 days in controls.  
Pig ischemia and ex 
vivo reperfusion/ 
transplantation [40] 
Cold Celsior preservation 
solution 
C3, caspase 3 
and 8, NF-
kB-p65 
siRNA Expression vector  apoptosis, myocardial damage, tissue 
inflammation, improved cardiac function 
Rat myocardial LAD 
ligation and 
reperfusion [*9] 
Intramyocardial injections 4 days 
before ischemia 
CD47 siRNA Viral vector  infarct size, serum myocardial 
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Rat myocardial LAD 
ligation and 
reperfusion [*10] 
Intramyocardial injection RAGE siRNA PEI and membrane-
penetrating delivery 
150 g  proinflammatory cytokines, apoptosis, 
myocardium fibrosis 
Rat myocardial LAD 
ligation and 
reperfusion [*11] 
Intramyocardial injections 1 h 
before ischemia 
SHP-1 siRNA DA-PEI vector 100 L apoptosis, infarct size 
Rat heart ischemia 
and ex vivo 
reperfusion [*12] 
Intramyocardial injection after 
ischemia 
CypD siRNA Viral vector  Dose-dependent protective on 
mitochondrial membrane potential 
Mouse myocardial 
LAD ligation and 
reperfusion [*13] 
Intramyocardial injection 10 min 
after ischemia 
PHD2 shRNA UTMD 25 g Improved fractional shortening, presence 
of small capillaries and venules in the 
infarcted zones, HIF-1 
Rat myocardial LAD 
ligation and 
reperfusion [*14] 
Intravenous injection 10 min 
after ischemia 




Intramyocardial injection 1 h 
after ischemia 
PHD2 siRNA Arg-G4 nanovector  10–200 nM PHD silencing in MSCs, apoptosis, 
fibrosis, angiogenesis, ventricular 
remodeling, improved heart function 
 
C3 = complement 3; CypD = cyclophilin D; DA = deoxycholic acid; eNOS = endothelial nitric oxide synthase; HIF-1 = hypoxia inducible factor 
1; LAD = left anterior descending artery; PHD2 = profyl hydroxylase domain enzyme 2; MSC = mesenchymal stem cell; mTOR = mammalian 
target of rapamycin; MyD88 = myeloid differentiation primary response 88; NO = nitric oxide; PEI = polyethyleneimine; RAGE = receptor 











This article is protected by copyright. All rights reserved 
shRNA = short hairpin RNA; TNF = tumor necrosis factor alpha; TRIF = TIR-domain-containing adapter-inducing interferon-; UTMD = 
ultrasound-targeted microbubble destruction; UW = University of Wisconsin. References with * are stated in supplementary file 1. 
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